Bocquet A., Dupont C., Chouraqui J. P., Darmaun D., Feillet F., Frelut M. L., Girardet J. P., Hankard R., Lapillonne A., Roze J. C., Simeoni U., Turck D., Briend André, Comm Nutr French Soc Pediat Cnsfp. (2019). Efficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy. Archives de Pédiatrie, 26 (4), p. 238-246. ISSN 0929-693X.
Titre du document
Efficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy
Année de publication
2019
Auteurs
Bocquet A., Dupont C., Chouraqui J. P., Darmaun D., Feillet F., Frelut M. L., Girardet J. P., Hankard R., Lapillonne A., Roze J. C., Simeoni U., Turck D., Briend André, Comm Nutr French Soc Pediat Cnsfp
Source
Archives de Pédiatrie, 2019,
26 (4), p. 238-246 ISSN 0929-693X
Foods for special medical purposes (FSMPs) with a protein fraction made of hydrolyzed rice protein (HRPs) have been on the market in Europe since the 2000s for the treatment of cow's milk protein allergy (CMPA). HRP formulas (HRPFs) are proposed as a plant-based alternative to cow's milk protein-based extensively hydrolyzed formulas (CMP-eHF) beside the soy protein formulas whose use in CMPA is controversial. HRPFs do not contain phytoestrogens and are derived from non-genetically modified rice. HRPFs are strictly plant-based apart from the addition of vitamin D-3 (cholecalciferol). As the amino acid content of rice proteins differs from that of human milk proteins, the protein quality of these formulas is improved by supplementation with free lysine, threonine, and tryptophan. The consumption of HRPFs has risen: for example, in France HRPFs account for 4.9% in volume of all formulas for children aged 0-3 years. Several studies have shown the adequacy of HRPFs in treating CMPA. They ensure satisfactory growth from the 1st weeks of life for infants and toddlers, both in healthy children and in those with CMPA. HRPFs can be used to treat children with CMPA either straightaway or in second intention in cases of poor tolerance to CMP-eHF for organoleptic reasons or for lack of efficacy. In France, the cost of HRPFs is close to that of regular infant or follow-on formulas.
Plan de classement
Santé : généralités [050]
;
Nutrition, alimentation [054]
Description Géographique
FRANCE ; ESPAGNE ; ITALIE ; EUROPE
Localisation
Fonds IRD [F B010075746]
Identifiant IRD
PAR00019467
